Filing Flows › Comparisons › IBO vs PULM
Impact Biomedical vs Pulmatrix: IBO and PULM compared
Impact Biomedical is the larger company: $3K of revenue in its latest quarter (Q2 2026) against $3K for Pulmatrix (Q4 2024). Impact Biomedical is growing faster (-57% against -100% a year earlier).
Where the money goes: IBO and PULM
Impact Biomedical (IBO) · Q2 2026
Impact Biomedical, Q2 2026: revenue $3K (-57% year over year), net loss $700K, operating cash flow $470K. The chart follows the revenue to costs, profit and cash.
Pulmatrix (PULM) · Q4 2024
Pulmatrix, Q4 2024: revenue $3K (-100% year over year), net loss $2.0M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Impact Biomedical (IBO) | Pulmatrix (PULM) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2024 |
| Revenue | $3K | $3K |
| Revenue growth, Y/Y | -57% | -100% |
| Operating margin | n/m | n/m |
| Net earnings | −$700K | −$2.0M |
| Operating cash flow | $470K | −$1.3M |
Questions
Which is bigger, Impact Biomedical or Pulmatrix?
Impact Biomedical is the larger company: $3K of revenue in its latest quarter (Q2 2026) against $3K for Pulmatrix (Q4 2024).
Is Impact Biomedical or Pulmatrix growing faster?
Impact Biomedical is growing faster (-57% against -100% a year earlier).
More: Impact Biomedical earnings · how Impact Biomedical makes money · Pulmatrix earnings · how Pulmatrix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 7, 2026; 10-K filed Mar 21, 2025). Fiscal quarters can end on different dates. Not investment advice.